# Bruton’s tyrosine kinase inhibitors in diffuse large B-cell lymphoma therapy: critical considerations and future innovations

**Authors:** Chuanyang Lu, Qiuni Chen, Yaodong Shen, Miaohong Chen, Yumeng Xie, Chunling Wang, Liang Yu

PMC · DOI: 10.1186/s12967-026-07798-8 · Journal of Translational Medicine · 2026-03-23

## Full-text entities

- **Genes:** MAPK1 (mitogen-activated protein kinase 1) [NCBI Gene 5594] {aka ERK, ERK-2, ERK2, ERT1, MAPK2, NS13}, MYD88 (MYD88 innate immune signal transduction adaptor) [NCBI Gene 4615] {aka IMD68, MYD88D, WM1}, BCL2 (BCL2 apoptosis regulator) [NCBI Gene 596] {aka Bcl-2, PPP1R50}, IBTK (inhibitor of Bruton tyrosine kinase) [NCBI Gene 25998] {aka BTBD26, BTKI}, NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790] {aka CVID12, EBP-1, KBF1, NF-kB, NF-kB1, NF-kappa-B1}, CD79B (CD79b molecule) [NCBI Gene 974] {aka AGM6, B29, IGB, Igbeta}, BCR (BCR activator of RhoGEF and GTPase) [NCBI Gene 613] {aka ALL, BCR1, CML, D22S11, D22S662, PHL}, PIK3CB (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta) [NCBI Gene 5291] {aka P110BETA, PI3K, PI3KBETA, PIK3C1}, MTOR (mechanistic target of rapamycin kinase) [NCBI Gene 2475] {aka FRAP, FRAP1, FRAP2, RAFT1, RAPT1, SKS}, BTK (Bruton tyrosine kinase) [NCBI Gene 695] {aka AGMX1, AT, ATK, BPK, IGHD3, IMD1}
- **Diseases:** DLBCL (MESH:D016403), R/R disease (MESH:D000069279), B-cell malignancies (MESH:D016393), lymphoma (MESH:D008223), B-NHL (MESH:D008228), MCD (MESH:D012514), Autoimmune Diseases (MESH:D001327)
- **Chemicals:** DZD8586 (-), Acalabrutinib (MESH:C000604908), Zanubrutinib (MESH:C000629551), Ibrutinib (MESH:C551803)
- **Species:** Homo sapiens (human, species) [taxon 9606]
- **Mutations:** C481S

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC13011641/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC13011641/full.md

---
Source: https://tomesphere.com/paper/PMC13011641